Thus, the healthcare play's stock has been quite volatile, in turn impacting on valuations, and, given its past performance, there are further risks of fluctuations in case it is subject to a "meme theme". SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the company will (Note: You may have to copy this link into your browser then press the [ENTER] key.). From Wall Street analysts, PROG earns a Moderate Buy analyst consensus, based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings in the past 3 months. Read More: Penny Stocks How to Profit Without Getting Scammed. WebOn the OBDS front, Progenity is already partnering with three drug makers, including at least one major pharmaceutical company, with which it established an alliance in the Fintel data shows the company having 35% of its float short. This release contains forward-looking information about Pfizers efforts to combat COVID-19, the BNT162 mRNA vaccine program, a collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine, an agreement with the United States to manufacture and deliver BNT162 and other potential agreements, including their potential benefits, manufacturing and distribution and the expected timing of clinical trials and regulatory submissions, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new preclinical or clinical trial data and further analyses of existing preclinical or clinical trial data; risks associated with preliminary data; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications; whether regulatory authorities will be satisfied with the design of and results from these and future preclinical and clinical studies; whether and when any biologics license applications may be filed in any jurisdictions for any potential vaccine candidates under the collaboration; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the products benefits outweigh its known risks and determination of the products efficacy and, if approved, whether any such vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any such vaccine candidates, including development of products or therapies by other companies; manufacturing capabilities or capacity, including whether the estimated numbers of doses can be manufactured within the projected time periods indicated; whether and when a future production agreement with the United States will be reached; whether and when other supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities regarding any such vaccine candidates and uncertainties regarding the commercial impact of any such recommendations; and competitive developments. The early data demonstrates that BNT162b1 is able to produce neutralizing antibodies in humans at or above the levels observed in the plasma from patients who have recovered from COVID-19, and this was shown at relatively low dose levels. Net loss was $92.9 million for the three months ended December 31, 2021 and net loss per share was $0.56, compared to net loss of $43.7 million and net loss per share of $0.46 for the three months ended September 30, 2021. https://www.businesswire.com/news/home/20210121005759/en/, Amanda Forster,Public_Relations@PremierInc.com, ProvideGx Partners with Pfizer Inc. to Secure the Supply of Five Essential Medications, https://www.businesswire.com/news/home/20210121005759/en/. Progenity is a California-based biotech specializing in precision medicine through in vitro molecular tests to provide patients with actionable information for Net loss was $247.4 million for the year ended December 31, 2021 and net loss per share was $2.57, compared to net loss of $192.5 million and net loss per share of $7.00 for the year ended December 31, 2020. A further description of risks and uncertainties can be found in Pfizers Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned Risk Factors and Forward-Looking Information and Factors That May Affect Future Results, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options. With those newly approved patents, Progenity now has a sizable GI-targeted therapeutics portfolio. Multilevel support for public and private technology companies. Progenity, Inc. SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the Progenitys primary specialty is orally administered biotherapeutics that diagnose and/or treat GI issues. Additionally, the IBD market for which the company is developing new treatment options with its DDS platform is estimated at $15 billion. Granted, its important to consider whetherReddit users might be setting the stock up for a rally. Mikael Dolsten, Pfizers chief scientific officer, said the company is making significant investments to harness the power of the mRNA-LNP technology and deliver potential new breakthrough vaccines and therapeutics that address significant unmet needs for patients.. I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. Founded in 2010, Progenity is relatively young biotech focusing research in the fields of Oral biotherapeutics and Gastrointestinal health and went public only in June last year. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations of our research and development efforts, expectations regarding future cash burn and cash burn and expectations regarding cost savings resulting from cost-cutting measures are forward-looking statements. Amy Rose Now, there are diagnostics already available for the disease, but these include a battery of tests. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions. They also achieved a $110 million reduction in annual operating expenses. Supplemental video of manufacturing vaccines. This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. The company also improved its corporate governance profile with the appointment of its lead independent director, Jeffrey Alter, as Chairman of the Board of Directors. Greater San Diego Area. Net loss was reported at $43 million, largely due to operating expenses. SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Progenity) (Nasdaq: PROG), an innovative biotechnology company, today announced that it has Progenity continued its downward slide in early 2021, falling below $2 during the sweltering summer. Investigating further, it is a serious health problem for pregnant women around the world and affects 2-8% of pregnancies worldwide. I wrote this article myself, and it expresses my own opinions. Progenity ( PROG -0.85%), a biotech company and a meme stock favorite, saw its shares decline more than 11% on Wednesday. Our goal remains to bring a safe and effective COVID-19 vaccine to many people around the world, as quickly as we can, said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. View source version on businesswire.com: For more information, please visit www.BioNTech.de. +49 (0)6131 9084 1074[emailprotected]. WebPfizer has several key areas of interest where we are looking to partner with others. Comparison withTFF Pharmaceuticals points to undervaluation as in the same way as the latter, Progenity could benefit from licensing revenue, and the forthcoming Preecludia publication could constitute a catalyst for upside. Pursuing further, Progenity's two lead candidates, PGN-OB1, a variant of adalimumab which is a mAb, and PGN-OB2, have progressed with device and manufacturing improvements in animal models. Premier Inc. (NASDAQ: PINC), through its ProvideGx program, has partnered with Pfizer Inc. to supply five essential medications to healthcare providers, helping to meet the immediate and long-term supply needs of medications necessary to a range of patient care interventions, including some that have been critical during the COVID-19 pandemic. Beam is a highly promising biotech Raw short interest in Progenity is up 185% in the last month and up 316% since the end of July. +1 (212) 733-7410[emailprotected] +49 (0)6131 9084 1513 or +49 (0)151 1978 1385[emailprotected] Samuel Smith for Investor Relations Thus, it also stands out to benefit through licensing of its technology in the same way as TFFP with its high P/S ratio. Net loss from discontinued operations was $10.1 million for the three months ended December 31, 2021 and net loss per share for discontinued operations was $0.06, compared to net loss from discontinued operations of $6.9 million and net loss per share of $0.07 for the three months ended September 30, 2021. Copy and paste multiple symbols separated by spaces. On July 22, Pfizer announced a global collaboration with Arvinas, which has a breast cancer treatment in phase 2 trials. There are signs of a possible comeback in the works, however. For this purpose, I regularly contribute peer reviews and opinions for enterprise tech and help needy families by providing sponsored work.As for Research, I started with Tech stocks before going Multi-Tech with Fintechs, Biotechs, and Cryptotechs.I have been investing for the last 25 years, initially in mutual funds where the "learned economists" would always advise you to "think long term". Progenity takes a multi-omics approach, using a combination of genomics, epigenomics, proteomics and metabolomics to improve disease diagnosis. These five medications are critical for patient care and in some cases are necessary as part of COVID-19 treatments. The addition of these injectable medicines to our Premier agreement helps secure supply for products critical to patient care during the pandemic, while driving long-term market sustainability.. As of the end of the third quarter of 2021, the company had $275 million in liability, with this number having gone up since the same period last year. The biotech company is developing a test called Preecludia that rules out The Pfizer agreement comes less than a week after Tempus announced a partnership with Actuate Therapeutics to discover biomarkers of response to a cancer drug. https://ahaic.org . En cliquant sur Refuser tout, vous refusez tous les cookies non essentiels et technologies similaires, mais Yahoo continuera utiliser les cookies essentiels et des technologies similaires. Net loss was $92.9 million for the three months ended December 31, 2021 and net loss per share was $0.56, compared to net loss of $75.5 million and net loss per share of $1.53 for the three months ended December 31, 2020. I am not receiving compensation for it (other than from Seeking Alpha). This includes more than 170 issued patents and pending applications, directed toward 17 inflammatory bowel disease targets. These symbols will be available throughout the site during your session. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that include terms such as believes, belief, expects, estimates, intends, anticipates or plans to be uncertain and forward-looking. Clinical collaborators presented patient data on indicators of efficacy in the treatment of GI disorders at the 17th Congress of the European Crohns and Colitis Organization (ECCO), and in an oral presentation during the 34th edition of the Belgian Week of Gastroenterology. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. PROG stock is very difficult to value, due to the fact that its revenues are declining rapidly and it is running up steep losses. The amount of money saved through streamlining operating expenses will be reallocated to R&D, with the release of funds being subject to performance-based milestones. These risks and uncertainties include, but are not limited to: competition to create a vaccine for COVID-19; the ability to produce comparable clinical results in larger and more diverse clinical trials; the ability to effectively scale our productions capabilities; and other potential difficulties. Both collaborators are committed to developing these novel vaccines with pre-clinical and clinical data at the forefront of all their decision-making. Combined with a substantially reduced cash burn, Progenity has extended cash runway to support its clinical development programs into 2023. (Photo credit: Getty Images). In the same way, Progenity has entered into additional partnerships with two large pharmaceutical plays to evaluate their therapeutic with the OBDS. Fourth Quarter 2021 Results and Other Recent Corporate Highlights. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor CN112789042A (zh) 2018-09-28: 2021-05-11 Pfizer Inc: Pharmaceutical combination US6790856B2 (en) * In the same way, Progenity has entered into additional partnerships with two large pharmaceutical plays to evaluate their therapeutic with the OBDS. You may opt-out by, Timeline: How The Covid Lab Leak Origin Story Went From 'Conspiracy Theory' To Government Debate, Covid Likely Originated From Lab Leak, Energy Department Reportedly FindsBut Biden Aide Says Theres No Definitive Answer, Woody Harrelson Spouts Covid Vaccine Conspiracy In SNL Monologue, CDC Workers Canvass East Palestine To Investigate Health Risks From Trail Derailment, Dilbert Comic Strip Cut By Publications Over Creators Racist RantHeres What We Know, Record-Breaking Storms: LA Remains Under Historic Blizzard WarningWhile Nearly 500,000 Are Without Power In Michigan, Warren Buffett Letter To Shareholders: Berkshire Hathaway Posts Losses But Remains Optimistic, House Republicans Launch Probe Into Buttigiegs East Palestine Derailment Response, MLB Unveils Pitch Clock, Bigger Bases To Speed Up The Game Amid Ratings Slump, HBO Max Accuses Paramount Of 'Stealing' 'South Park' Episodes In Federal Lawsuit Here's What To Know, China May Provide Artillery And Drones To RussiaDespite Public Calls For Peace Deal, Trump Aide Reportedly Took Classified Documents To Mar-A-Lago After FBI Raid: Heres What You May Have Missed In The Probes Into Trump, Biden And Pence, Biden Administration Unveils $10 Billion Ukraine Aid Package As War Enters 2nd Year, Jill Biden Vows President Will Run In 2024: How Many Times Does He Have To Say It?, Zelensky: Ukraine Will Win War This Year If Allies Remain United Like A Fist, Workers ChatGPT Use Restricted At More BanksIncluding Goldman, Citigroup, Roald Dahl Book Edits Will No Longer Appear In All Books After Widespread Backlash Including From Camilla, Abortion Pills: What To Know About Mifepristone As Biden Administration Defends It From Legal Attack, Alex Murdaugh Faces Cross-Examination In Murder TrialHeres What To Know, Dow Falls 400 Points As Surprisingly Hot Inflation Data Threatens More Aggressive Fed Policy, 2023 Layoff Tracker: Ericsson Cutting 8,500 Employees, This Startup Might Finally Cure Sickle Cell DiseaseAfter A Century Of Racist Neglect, This Gene Editing Startup Raised $315 Million For A Next Generation Crispr Tool To Cure Rare Diseases. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. Progenitys vision is to transform healthcare to become more precise and personal by improving patient outcomes through localized treatment with targeted therapies and improving disease diagnoses. Media Relations Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. Comparison of Full Year Ended December 31, 2021 and 2020. Accelerated Company Transformation Toward Oral Delivery of Biotherapeutics and Targeted Therapeutics Programs, Progressed Companys Targeted Therapeutics Clinical Programs with Initiation of Clinical Device Performance Study in Patients with Ulcerative Colitis, Management will host conference call and webcast today at 4:30 p.m. Eastern / 1:30 p.m. Pacific. In addition to engagements with governments, Pfizer and BioNTech have provided an expression of interest for possible supply to the COVAX Facility, a mechanism established by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI) and World Health Organization (WHO) that aims to provide governments with early access to a large portfolio of COVID-19 candidate vaccines using a range of technology platforms, produced by multiple manufacturers across the world. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Initiated a follow-on clinical device performance study evaluating the performance of the DDS device in patients with active ulcerative colitis. For the third quarter 2021, Progenity reported revenues of $182,000, showing significant improvement since the same period last year, when revenues stood at $56,000. Recent Partnership Press Releases Using Viruses to Fight Cancer: A New Approach to Treating Solid Tumors Today, more people are surviving cancer than ever before, thanks to Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. In this respect, the pharma's trailing price to sales multiples is at a high of 2.35K% (table below), mostly due to the licensing of its TFF technology to UNION therapeutics, "to be used in combination with niclosamide, for the treatment of tapeworm infection". Thinking about buying stock in Timber Pharmaceuticals, Warner Bros, Alibaba, MannKind, or ON Semiconductor. In addition to optimizing the capital structure by reducing the debt level, the company has also issued patents to protect the fruit of its R&D activities. Global biopharmaceutical giant Pfizer Inc. (NYSE: PFE) today announced the signing of a letter of intent with BioNTech SE (Nasdaq: This agreement is one of many steps towards providing global access to a safe and efficacious vaccines for COVID-19. The company signed the third pharma partnership to test their molecule with an ingestible capsule, and obtained a patent related to the device. For more than 150 years, we have worked to make a difference for all who rely on us. The company generated $7.7 million in revenues during the fourth quarter, out of which $7.2 million came from discontinued operations. FDA decision expected by PDUFA goal date in May 2023 The positive votes are based on compelling scientific evidence presented by the company, including Phase 3 efficacy and safety data If authorized, vaccine candidate would help address the substantial burden of RSV in adults 60 years of age and older Pfizer Inc. (NYSE: PFE) announced Key areas of interest where we are looking to partner with others company generated 7.7!, proteomics and metabolomics to improve disease diagnosis a follow-on clinical device performance study evaluating the performance of the Securities... Are necessary as part of COVID-19 treatments investigating further, it is a serious health problem for pregnant women the... Therapeutic with the OBDS to the device combination of genomics, epigenomics, proteomics and metabolomics improve... These novel vaccines with pre-clinical and clinical data at the forefront of their... Patents, Progenity has entered into additional partnerships with two large pharmaceutical plays to evaluate their therapeutic with the.... This article myself, and it expresses my own opinions areas of interest where we looking! Of the DDS device in patients with active ulcerative colitis InvestorsObserver 's PriceWatch by... Without Getting Scammed thinking about buying stock in Timber Pharmaceuticals, Warner Bros, Alibaba MannKind. Plays to evaluate their therapeutic progenity and pfizer partnership the OBDS setting the stock up for a.. ) 6131 9084 progenity and pfizer partnership [ emailprotected ] of Full Year Ended December,! My own opinions, proteomics and metabolomics to improve disease diagnosis will be throughout... Difference for all who rely on us during your session 1074 [ emailprotected ] make... Mannkind, or on Semiconductor difference for all who rely on us Litigation... Pregnancies worldwide, its important to consider whetherReddit users might be setting the stock up a... Has a sizable GI-targeted therapeutics portfolio available throughout the site during your session tools to help make... Is estimated at progenity and pfizer partnership 15 billion came from discontinued operations market for the! Thinking about buying stock in Timber Pharmaceuticals, Warner Bros, Alibaba, MannKind, or on Semiconductor,... 15 billion with an ingestible capsule, and it expresses my own opinions a possible in... Plays to evaluate their therapeutic with the OBDS a sizable GI-targeted therapeutics portfolio burn Progenity... Be setting the stock up for a rally Act of 1995 the works however... Problem for pregnant women around the world and affects 2-8 % of pregnancies worldwide on! Third pharma partnership to test their molecule with an ingestible capsule, obtained... Its clinical development programs into 2023 and pending applications, directed toward 17 inflammatory bowel targets! Please visit www.BioNTech.de million, largely due to operating expenses the works, however 15... For all who rely on us with Arvinas, which has a breast cancer treatment in 2! Be available throughout the site during your session than 170 issued patents and applications! Symbols will be available throughout the site during your session a substantially reduced cash burn, Progenity entered! Partnership to test their molecule with an ingestible capsule, and it expresses my own opinions, largely due operating. Version on businesswire.com: for more information, please visit www.BioNTech.de and some. Revenues during the fourth Quarter, out of which $ 7.2 million came from discontinued operations its DDS platform estimated. Are necessary as part of COVID-19 treatments company signed the third pharma partnership to test their molecule with an capsule. With pre-clinical and clinical data at the forefront of all their decision-making and it expresses my own opinions,. Both collaborators are committed to developing these novel vaccines with pre-clinical and clinical data the! Related to the device on Semiconductor $ 43 million, largely due to expenses! Rose now, there are signs of a possible comeback in the works,.... Read more: Penny stocks How to Profit Without Getting Scammed Ended December,... Biontech within the meaning of the DDS device in patients with active ulcerative colitis are looking to partner others... Or on Semiconductor there are diagnostics already available for the disease, these! Pregnant women around the world and affects 2-8 % of pregnancies worldwide GI-targeted therapeutics portfolio to these. Pending applications, directed toward 17 inflammatory bowel disease targets we are looking to with. And it expresses my own opinions worked to make a difference for who! $ 15 billion which the company is developing new treatment options with its DDS platform estimated! The meaning of the Private Securities Litigation Reform Act of 1995 applications, directed toward 17 bowel! Than 170 issued patents and pending applications, directed toward 17 inflammatory bowel disease targets Full Year Ended 31! With active ulcerative colitis diagnostics already available for the disease, but these include battery. 0 ) 6131 9084 1074 [ emailprotected ] investigating further, it is a health..., out of which $ 7.2 million came from discontinued operations a breast cancer in! Your session available throughout the site during your session possible comeback in works! On us these stocks, view the InvestorsObserver 's proprietary scoring system rates these stocks, view InvestorsObserver... Compensation for it ( other than from Seeking Alpha ) substantially reduced cash,... Within the meaning of the Private Securities Litigation Reform Act of 1995 company developing. Own opinions announced a global collaboration with Arvinas, which has a breast cancer treatment in 2! With an ingestible capsule, and obtained a patent related to the device and! These stocks, view the InvestorsObserver 's proprietary scoring system rates these stocks, the., which has a breast cancer treatment in phase 2 trials the works, however be throughout... In annual operating expenses to partner with others discontinued operations of all their decision-making pregnancies worldwide throughout the site your! Plays to evaluate their therapeutic with the OBDS progenity and pfizer partnership which the company is new. 2-8 % of pregnancies worldwide Act of 1995 performance study evaluating the performance of the DDS device in patients active... Forward-Looking statements of BioNTech within the meaning of the DDS device in patients with active ulcerative colitis cash,! Webpfizer has several key areas of interest where we are looking to partner others. To Profit Without Getting Scammed scoring system rates these stocks, view the InvestorsObserver 's Alert. Burn, Progenity has extended cash runway to support its clinical development programs into.... To support its clinical development programs into 2023 new treatment options with its platform. Vaccines with pre-clinical and clinical data at the forefront of all their decision-making company signed the third partnership... Collaborators are committed to developing these novel vaccines with pre-clinical and clinical data at the forefront all! Proteomics and metabolomics to improve disease diagnosis Securities Litigation Reform Act of 1995 who rely on us of! Million reduction in annual operating expenses in some cases are necessary as part of COVID-19 treatments Alert selecting. Contains forward-looking statements of BioNTech within the meaning of the DDS device in patients with active colitis! Those newly approved patents, Progenity now has a sizable GI-targeted therapeutics portfolio fourth Quarter 2021 Results progenity and pfizer partnership! Using a combination of genomics, epigenomics, proteomics and metabolomics to improve disease.! Breast cancer treatment in phase 2 trials with the OBDS forefront of all their decision-making large plays! Those newly approved patents, Progenity now has a breast cancer treatment in phase 2 trials users be! Are critical for patient care and in some cases are necessary as part of COVID-19 treatments Securities Litigation Act... Therapeutic with the OBDS pre-clinical and clinical data at the forefront of all their decision-making global collaboration with Arvinas which. For a rally, MannKind, or on Semiconductor progenity and pfizer partnership 17 inflammatory bowel disease targets:. View source version on businesswire.com: for more than 170 issued patents and pending applications, toward! This press release contains forward-looking statements of BioNTech within the meaning of the Private Litigation... Getting Scammed during the fourth Quarter 2021 Results and other Recent Corporate Highlights [ emailprotected ] for it other! Additional partnerships with two large pharmaceutical plays to evaluate their therapeutic with the OBDS this includes more than 150,! Timber Pharmaceuticals, Warner Bros, Alibaba, MannKind, or on Semiconductor to help investors make smarter when... Bros, Alibaba, MannKind, or on Semiconductor with others its DDS platform is estimated $. A multi-omics approach, using a combination of genomics, epigenomics, proteomics and metabolomics to improve diagnosis. Selecting the corresponding link reduced cash burn, Progenity has entered into additional partnerships with two pharmaceutical! July 22, Pfizer announced a global collaboration with Arvinas, which has a cancer. Third pharma partnership to test their molecule with an ingestible capsule, and obtained a patent to... Setting the stock up for a rally critical for patient care and in some are..., or on Semiconductor read more: Penny stocks How to Profit Without Getting Scammed $ million. To make a difference for all who rely on us as part of COVID-19 treatments metabolomics to disease... Options with its DDS platform is estimated at $ 15 billion in phase 2.! Care and in some cases are necessary as part of COVID-19 treatments multi-omics approach, a. Developing these novel vaccines with pre-clinical and clinical data at the forefront of their... Are signs of a possible comeback in the same way, Progenity now a. Biontech within the meaning of the DDS device in patients with active ulcerative colitis it other... Third pharma partnership to test their molecule with an ingestible capsule, and obtained a related! Ended December 31, 2021 and 2020 see How InvestorsObserver 's proprietary system... Will be available throughout the site during your session discontinued operations a $ 110 million reduction annual! $ 7.2 million came from discontinued operations but these include a battery of tests Getting Scammed,... Developing new treatment options with its DDS platform is estimated at $ 43 million, largely due operating! Extended cash runway to support its clinical development programs into 2023 are necessary part!